Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: Structured Ecosystems Therapy (SET), Individually tailored intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV
Interventions: no intervention; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: RSV Infection
Interventions: Candidate vaccine, SCB-1019T, AREXVY, placebo; Biological · Other
Lead sponsor: Clover Biopharmaceuticals USA, LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more

Conditions: Opiate Dependence, HIV Infections
Interventions: Buprenorphine/Subutex, Naltrexone, Drug counseling; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 24
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 16 more

Conditions: Hepatitis C
Interventions: Omega-3 Fatty Acids, Placebo comparator; Dietary Supplement · Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Chronic Hepatitis C
Interventions: 20mg ezetimibe, Placebo, 40mg ezetimibe; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Human Immunodeficiency Virus
Interventions: Genital and rectal swabbing; Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions: Patient Safety health information technology; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 21,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tachycardia, Dyspnea, COVID-19
Interventions: Metoprolol Succinate; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 40 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Catheterization
Interventions: Hydrogel Silver Salts Coated Latex Urinary Catheter System, Bard silicone elastomer coated latex catheter system; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Surgical Site Infection in Obese Women Undergoing C-section
Interventions: cephalexin & metronidazole, placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 13 Years and older · Female only
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 18
States / cities: Birmingham, Alabama • San Francisco, California • San Jose, California + 11 more

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Optimune oral nutritional supplement; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 12 more

Conditions: HIV, STIs, STIs Prevention, HIV Prevention
Interventions: Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9; Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 24 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more

Conditions: Intestinal Failure, CRBSI - Catheter Related Bloodstream Infection
Interventions: Sodium bicarb lock; Drug
Lead sponsor: Riad Rahhal; Other
Eligibility: 1 Year to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Risk Behavior, Sexually Transmitted Diseases
Interventions: Community-Popular Opinion Leader Model, Diffusion of Innovations; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: College Station, Texas

Conditions: ART Adherence
Interventions: TXTXT, e-Navigation, Ecological Momentary Assessment (EMA) supported e-Navigation.; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HPV Infection, Vaccine-Preventable Diseases
Interventions: HPV game; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 19
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Major Cutaneous Abscess, Cellulitis, Erysipelas
Interventions: TR701 FA; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 7 more

Conditions: Healthy Volunteers
Interventions: Immulina TM, Placebo; Drug · Dietary Supplement
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Pneumonitis, SARS-CoV Infection
Interventions: GLS-1027, Placebo; Drug
Lead sponsor: GeneOne Life Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Search by objective public record fields.

Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

HIV Risk Reduction and Drug Abuse Treatment in Iran

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

Problems With Immune Recovery in the Gut Tissue

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study

Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)

Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery

Evaluation of Patients Who Have Not Had Success With Zidovudine

A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss

Combatting HIV Or Other STIs Early (CHOOSE)

8.4% Sodium Bicarbonate Locks in Intestinal Failure

A Community-Based Intervention With Popular Opinion Leaders (C-POL) in Texas

Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV

Game-Based Intervention to Promote HPV Vaccination

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)